Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.0%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 6,500 shares, a decrease of 57.0% from the October 15th total of 15,100 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 127,000 shares, the short-interest ratio is presently 0.1 days.

Estrella Immunopharma Price Performance

ESLA remained flat at $0.84 on Thursday. The company’s stock had a trading volume of 3,930 shares, compared to its average volume of 78,063. The stock has a market cap of $30.40 million, a P/E ratio of -0.42 and a beta of 0.24. The firm’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.10. Estrella Immunopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Friday, September 27th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.